Beijing Konruns Pharmaceutical Co.,Ltd.
SSE:603590.SS
31.3 (CNY) • At close June 6, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 825.398 | 920.012 | 866.726 | 809.782 | 808.644 | 1,065.925 | 1,022.164 | 590.58 | 346.225 | 436.148 | 544.488 | 598.385 |
| Kosten van de omzet
| 86.125 | 101.049 | 126.157 | 105.759 | 59.249 | 57.662 | 50.045 | 44.971 | 38.184 | 41.219 | 35.577 | 29.789 |
| Brutowinst
| 739.272 | 818.962 | 740.568 | 704.023 | 749.395 | 1,008.263 | 972.119 | 545.609 | 308.041 | 394.928 | 508.911 | 568.595 |
| Brutowinstmarge
| 0.896 | 0.89 | 0.854 | 0.869 | 0.927 | 0.946 | 0.951 | 0.924 | 0.89 | 0.905 | 0.935 | 0.95 |
| Onderzoek- en ontwikkelingskosten
| 54.938 | 94.911 | 86.776 | 102.269 | 93.107 | 108.785 | 80.248 | 32.166 | 38.39 | 38.725 | 0 | 0 |
| Algemene en administratieve kosten
| 50.724 | 39.584 | 33.147 | 32.201 | 24.832 | 8.669 | 13.626 | 7.896 | 5.431 | 32.728 | 65.765 | 64.07 |
| Verkoop- en marketingkosten
| -103.846 | 472.585 | 423.153 | 391.284 | 473.15 | 637.205 | 602.898 | 291.313 | 76.976 | 133.782 | 270.577 | 382.645 |
| Verkoop-, algemene en administratieve kosten
| -53.122 | 512.169 | 456.301 | 423.485 | 497.983 | 645.873 | 616.523 | 299.209 | 82.407 | 166.51 | 336.342 | 446.715 |
| Overige kosten
| 698.369 | 68.599 | 60.266 | 45.484 | 9.664 | 12.273 | 0.175 | 18.405 | 10.334 | 18.674 | 12.797 | 17.185 |
| Bedrijfskosten
| 700.185 | 675.679 | 603.342 | 571.238 | 600.754 | 766.931 | 708.32 | 354.002 | 145.558 | 230.276 | 344.86 | 456.386 |
| Bedrijfsresultaat
| 39.088 | 143.283 | 140.704 | 192.294 | 210.223 | 299.511 | 300.036 | 556.905 | 207.843 | 203.747 | 190.394 | 118.722 |
| Bedrijfsresultaat ratio
| 0.047 | 0.156 | 0.162 | 0.237 | 0.26 | 0.281 | 0.294 | 0.943 | 0.6 | 0.467 | 0.35 | 0.198 |
| Totaal overige inkomsten en kosten netto
| -0.224 | -20.55 | -0.387 | -3.437 | -2.2 | -0.42 | 0.175 | 18.197 | 10.334 | 18.674 | 9.117 | 16.79 |
| Inkomen voor belasting
| 38.864 | 122.733 | 140.317 | 188.857 | 208.024 | 299.091 | 300.211 | 575.31 | 218.177 | 222.421 | 199.511 | 135.512 |
| Inkomen voor belasting ratio
| 0.047 | 0.133 | 0.162 | 0.233 | 0.257 | 0.281 | 0.294 | 0.974 | 0.63 | 0.51 | 0.366 | 0.226 |
| Belastingkosten
| 17.333 | -64.839 | 16.422 | 21.415 | 24.669 | 33.011 | 36.282 | 96.493 | 26.524 | 27.171 | 23.649 | 16.566 |
| Nettowinst
| 42.217 | 150.451 | 101.49 | 147.986 | 183.359 | 266.08 | 263.93 | 478.817 | 191.653 | 195.251 | 175.897 | 118.437 |
| Nettowinstmarge
| 0.051 | 0.164 | 0.117 | 0.183 | 0.227 | 0.25 | 0.258 | 0.811 | 0.554 | 0.448 | 0.323 | 0.198 |
| WPA (Winst Per Aandeel)
| 0.27 | 0.96 | 0.65 | 0.94 | 1.15 | 1.66 | 1.98 | 3.99 | 1.6 | 1.63 | 1.47 | 0.99 |
| Verwaterde WPA
| 0.27 | 0.96 | 0.65 | 0.94 | 1.15 | 1.66 | 1.98 | 3.99 | 1.6 | 1.63 | 1.47 | 0.99 |
| EBITDA
| 81.478 | 168.067 | 189.967 | 226.099 | 238.853 | 240.237 | 334.789 | 246.018 | 217.125 | 189.623 | 186.299 | 139.349 |
| EBITDA ratio
| 0.099 | 0.183 | 0.219 | 0.279 | 0.295 | 0.225 | 0.328 | 0.417 | 0.627 | 0.435 | 0.342 | 0.233 |